{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:54:01Z","timestamp":1791298441915,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumor, with a small proportion of patients presenting with advanced disease. The recent European Society of Endocrine Surgeons (ESES) consensus introduced a refined definition of advanced thyroid cancer. This study aimed to characterize real-world clinical features, treatment patterns, and surgical outcomes of patients with advanced PTC according to the updated ESES definition treated at a high-volume endocrine surgery center. This monocentric, retrospective cohort study included all patients who underwent primary surgery for advanced PTC at a high-volume endocrine surgery center between 2015 and 2023. Clinical data originated from our own patients in the EUROCRINE\n                    <jats:sup>\u00ae<\/jats:sup>\n                    registry. A total of 33 patients with advanced PTC were included. Median age at diagnosis was 54\u00a0years, 52% were male, and median Charlson Comorbidity Index (CCI) was 2, indicating a low comorbidity burden. Among patients disease-free after surgery (n = 27), 11 (41%) experienced tumor recurrence, most frequently in lymph nodes and lung combined (36%) or in lymph nodes alone (27%). Median recurrence-free survival was 98\u00a0months. Patients with persistent disease after surgery had a poor prognosis, with a median progression-free survival of 4.5\u00a0months. Age &gt; 55\u00a0years was associated with reduced overall survival (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.007), while male sex was associated with increased recurrence risk (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.047); both findings should be interpreted with caution. Despite advanced disease, most patients achieved disease-free status after primary surgery, with the majority being alive at last follow-up. Due to the limited sample size and missing follow-up data for some patients, these findings should be taken with caution, and larger studies are needed to confirm potential predictors of survival and recurrence.\n                  <\/jats:p>","DOI":"10.1007\/s13304-026-02875-5","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:35:46Z","timestamp":1791297346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recurrence patterns and survival outcomes in advanced papillary thyroid carcinoma: a retrospective cohort analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7984-9530","authenticated-orcid":false,"given":"Ann-Kathrin","family":"Lederer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia I.","family":"Staubitz-Vernazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Lozan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Oliver Metzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Musholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"2875_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1530\/ETJ-22-0027","volume":"11","author":"M Grussendorf","year":"2022","unstructured":"Grussendorf M, Ruschenburg I, Brabant G (2022) Malignancy rates in thyroid nodules: a long-term cohort study of 17592 patients. Eur Thyroid J 11:27. https:\/\/doi.org\/10.1530\/ETJ-22-0027","journal-title":"Eur Thyroid J"},{"key":"2875_CR2","unstructured":"Leitlinienprogramm Onkologie der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) sowie der Deutschen Krebsgesellschaft e.V. (DKG) und der Stiftung Deutsche Krebshilfe (DKH) (2025) S3-Leitlinie Schilddr\u00fcsenkarzinom"},{"key":"2875_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1089\/thy.2023.0709","volume":"34","author":"DW Chen","year":"2024","unstructured":"Chen DW, Carr G, Worden FP et al (2024) Survival prognostication in patients with differentiated thyroid cancer and distant metastases: A SEER population-based study. Thyroid\u00ae 34:837\u2013845. https:\/\/doi.org\/10.1089\/thy.2023.0709","journal-title":"Thyroid\u00ae"},{"key":"2875_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/bjs\/znae199","volume":"111","author":"M Raffaelli","year":"2024","unstructured":"Raffaelli M, Voloudakis N, Barczynski M et al (2024) European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management. Br J Surg 111:199. https:\/\/doi.org\/10.1093\/bjs\/znae199","journal-title":"Br J Surg"},{"key":"2875_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621\u2013630. https:\/\/doi.org\/10.1056\/NEJMoa1406470","journal-title":"N Engl J Med"},{"key":"2875_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384:319\u2013328. https:\/\/doi.org\/10.1016\/S0140-6736(14)60421-9","journal-title":"Lancet"},{"key":"2875_CR7","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1245\/s10434-013-2984-8","volume":"20","author":"BH-H Lang","year":"2013","unstructured":"Lang BH-H, Lo C-Y, Wong KP, Wan KY (2013) Should an involved but functioning recurrent laryngeal nerve be shaved or resected in a locally advanced papillary thyroid carcinoma? Ann Surg Oncol 20:2951\u20132957. https:\/\/doi.org\/10.1245\/s10434-013-2984-8","journal-title":"Ann Surg Oncol"},{"key":"2875_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/cancers16010163","volume":"16","author":"JI Staubitz-Vernazza","year":"2023","unstructured":"Staubitz-Vernazza JI, Schwind S, Lozan O, Musholt TJ (2023) A 16-year single-center series of trachea resections for locally advanced thyroid carcinoma. Cancers (Basel) 16:163. https:\/\/doi.org\/10.3390\/cancers16010163","journal-title":"Cancers (Basel)"},{"key":"2875_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/bjs.10655","volume":"105","author":"HI Kim","year":"2018","unstructured":"Kim HI, Kim TH, Choe J-H et al (2018) Surgeon volume and prognosis of patients with advanced papillary thyroid cancer and lateral nodal metastasis. Br J Surg 105:270\u2013278. https:\/\/doi.org\/10.1002\/bjs.10655","journal-title":"Br J Surg"},{"key":"2875_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"2875_CR11","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1002\/cncr.26425","volume":"118","author":"LA Niemeier","year":"2012","unstructured":"Niemeier LA, Kuffner Akatsu H, Song C et al (2012) A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. Cancer 118:2069\u20132077. https:\/\/doi.org\/10.1002\/cncr.26425","journal-title":"Cancer"},{"key":"2875_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.surg.2007.06.011","volume":"143","author":"I Sugitani","year":"2008","unstructured":"Sugitani I, Fujimoto Y, Yamamoto N (2008) Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery 143:35\u201342. https:\/\/doi.org\/10.1016\/j.surg.2007.06.011","journal-title":"Surgery"},{"key":"2875_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-08845-y","volume":"15","author":"J Dan","year":"2025","unstructured":"Dan J, Tan J, Guo Y et al (2025) Survival benefits of primary tumor resection in metastatic differentiated thyroid cancer: an analysis of SEER data. Sci Rep 15:21932. https:\/\/doi.org\/10.1038\/s41598-025-08845-y","journal-title":"Sci Rep"},{"key":"2875_CR14","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000046","author":"DLS Danilovic","year":"2018","unstructured":"Danilovic DLS, Castro G, Roitberg FSR et al (2018) Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer. Arch Endocrinol Metab. https:\/\/doi.org\/10.20945\/2359-3997000000046","journal-title":"Arch Endocrinol Metab"},{"key":"2875_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.21873\/cdp.10421","volume":"5","author":"K Tsuchida","year":"2025","unstructured":"Tsuchida K, Shiga K, Katagiri K et al (2025) Successful salvage of four cases of unresectable papillary thyroid cancer following lenvatinib administration. Cancer Diagn Prog 5:127\u2013131. https:\/\/doi.org\/10.21873\/cdp.10421","journal-title":"Cancer Diagn Prog"},{"key":"2875_CR16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/lary.23548","volume":"123","author":"GM Gardner","year":"2013","unstructured":"Gardner GM, Smith MM, Yaremchuk KL, Peterson EL (2013) The cost of vocal fold paralysis after thyroidectomy. Laryngoscope 123:1455\u20131463. https:\/\/doi.org\/10.1002\/lary.23548","journal-title":"Laryngoscope"},{"key":"2875_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00104-015-0125-6","volume":"87","author":"H Dralle","year":"2016","unstructured":"Dralle H, Neu J, Musholt TJ, Nies C (2016) Bilaterale Stimmlippenparese nach totaler Thyreoidektomie. Chirurg 87:65\u201368. https:\/\/doi.org\/10.1007\/s00104-015-0125-6","journal-title":"Chirurg"},{"key":"2875_CR18","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00268-014-2906-3","volume":"39","author":"HS Lee","year":"2015","unstructured":"Lee HS, Kim SW, Park T et al (2015) Papillary thyroid carcinoma with exclusive involvement of a functioning recurrent laryngeal nerve may be treated with shaving technique. World J Surg 39:969\u2013974. https:\/\/doi.org\/10.1007\/s00268-014-2906-3","journal-title":"World J Surg"},{"key":"2875_CR19","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.4103\/jhnps.jhnps_6_24","volume":"12","author":"A Vaidya","year":"2024","unstructured":"Vaidya A, Kapre M (2024) Chapter 4: surgery for locally advanced thyroid cancers. J Head Neck Phys Surg 12:S16\u2013S21. https:\/\/doi.org\/10.4103\/jhnps.jhnps_6_24","journal-title":"J Head Neck Phys Surg"},{"key":"2875_CR20","doi-asserted-by":"publisher","first-page":"7157","DOI":"10.1245\/s10434-023-14142-7","volume":"30","author":"HS Lee","year":"2023","unstructured":"Lee HS, Kim Y, Kim SB et al (2023) Shaving papillary thyroid carcinoma involving functioning recurrent laryngeal nerve: safety of incomplete tumor resection and nerve sparing. Ann Surg Oncol 30:7157\u20137164. https:\/\/doi.org\/10.1245\/s10434-023-14142-7","journal-title":"Ann Surg Oncol"},{"key":"2875_CR21","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1089\/thy.2012.0011","volume":"22","author":"D Giordano","year":"2012","unstructured":"Giordano D, Valcavi R, Thompson GB et al (2012) Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. Thyroid 22:911\u2013917. https:\/\/doi.org\/10.1089\/thy.2012.0011","journal-title":"Thyroid"},{"key":"2875_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjorl.2023.101318","volume":"89","author":"Y Li","year":"2023","unstructured":"Li Y, Lao L (2023) Comparison of prophylactic ipsilateral and bilateral central lymph node dissection in papillary thyroid carcinoma: a meta-analysis. Braz J Otorhinolaryngol 89:101318. https:\/\/doi.org\/10.1016\/j.bjorl.2023.101318","journal-title":"Braz J Otorhinolaryngol"},{"key":"2875_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00104-025-02275-2","volume":"96","author":"A-K Lederer","year":"2025","unstructured":"Lederer A-K, Musholt TJ (2025) Update papill\u00e4res Schilddr\u00fcsenkarzinom\u2014Was ist f\u00fcr Chirurg*innen relevant? Chirurgie 96:537\u2013543. https:\/\/doi.org\/10.1007\/s00104-025-02275-2","journal-title":"Chirurgie"},{"key":"2875_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194323","volume":"10","author":"G Perigli","year":"2021","unstructured":"Perigli G, Cianchi F, Giudici F et al (2021) Thyroidectomy for cancer: the surgeon and the parathyroid glands sparing. J Clin Med 10:4323. https:\/\/doi.org\/10.3390\/jcm10194323","journal-title":"J Clin Med"},{"key":"2875_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"2875_CR26","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1002\/hed.27865","volume":"46","author":"L Min","year":"2024","unstructured":"Min L, Weng Y, Li Y et al (2024) Comparison of unilateral versus bilateral central neck dissection for clinically invasive papillary thyroid carcinoma. Head Neck 46:2244\u20132252. https:\/\/doi.org\/10.1002\/hed.27865","journal-title":"Head Neck"},{"key":"2875_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3389\/fendo.2022.777345","volume":"13","author":"AK Siraj","year":"2022","unstructured":"Siraj AK, Parvathareddy SK, Annaiyappanaidu P et al (2022) Male sex is an independent predictor of recurrence-free survival in middle eastern papillary thyroid carcinoma. Front Endocrinol (Lausanne) 13:345. https:\/\/doi.org\/10.3389\/fendo.2022.777345","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2875_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60199-9","volume":"10","author":"J Ding","year":"2020","unstructured":"Ding J, Wu W, Fang J et al (2020) Male sex is associated with aggressive behaviour and poor prognosis in Chinese papillary thyroid carcinoma. Sci Rep 10:4141. https:\/\/doi.org\/10.1038\/s41598-020-60199-9","journal-title":"Sci Rep"},{"key":"2875_CR29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12885-018-4181-4","volume":"18","author":"RM Kauffmann","year":"2018","unstructured":"Kauffmann RM, Hamner JB, Ituarte PHG, Yim JH (2018) Age greater than 60 years portends a worse prognosis in patients with papillary thyroid cancer: should there be three age categories for staging? BMC Cancer 18:316. https:\/\/doi.org\/10.1186\/s12885-018-4181-4","journal-title":"BMC Cancer"},{"key":"2875_CR30","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1200\/JCO.2016.68.9372","volume":"34","author":"MA Adam","year":"2016","unstructured":"Adam MA, Thomas S, Hyslop T et al (2016) Exploring the relationship between patient age and cancer-specific survival in papillary thyroid cancer: rethinking current staging systems. J Clin Oncol 34:4415\u20134420. https:\/\/doi.org\/10.1200\/JCO.2016.68.9372","journal-title":"J Clin Oncol"},{"key":"2875_CR31","doi-asserted-by":"publisher","first-page":"18346","DOI":"10.18632\/oncotarget.7811","volume":"7","author":"L Jin","year":"2016","unstructured":"Jin L, Chen E, Dong S et al (2016) BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget 7:18346\u201318355. https:\/\/doi.org\/10.18632\/oncotarget.7811","journal-title":"Oncotarget"},{"key":"2875_CR32","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/cen.14316","volume":"94","author":"B Chen","year":"2021","unstructured":"Chen B, Shi Y, Xu Y, Zhang J (2021) The predictive value of coexisting BRAF V600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 94:731\u2013742. https:\/\/doi.org\/10.1111\/cen.14316","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2875_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00839","author":"TP de Castro","year":"2019","unstructured":"de Castro TP, Penha RCC, Buexm LA et al (2019) Molecular predictors for advanced papillary thyroid carcinoma recurrence. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2019.00839","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2875_CR34","doi-asserted-by":"publisher","first-page":"6303","DOI":"10.1007\/s00432-022-04541-w","volume":"149","author":"Z Ding","year":"2023","unstructured":"Ding Z, Tao X, Deng X et al (2023) Genetic analysis and clinicopathologic features of locally advanced papillary thyroid cancers: a prospective observational study. J Cancer Res Clin Oncol 149:6303\u20136313. https:\/\/doi.org\/10.1007\/s00432-022-04541-w","journal-title":"J Cancer Res Clin Oncol"},{"key":"2875_CR35","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.21873\/anticanres.17128","volume":"44","author":"S Toda","year":"2024","unstructured":"Toda S, Saito N, Kadoya M et al (2024) Association of BRAF or TERT promoter mutations and advanced papillary thyroid carcinoma. Anticancer Res 44:3141\u20133147. https:\/\/doi.org\/10.21873\/anticanres.17128","journal-title":"Anticancer Res"},{"key":"2875_CR36","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1089\/thy.2024.0691","volume":"35","author":"I Marion","year":"2025","unstructured":"Marion I, Schulz S, Glasner C et al (2025) Deep learning discovers new morphological features while predicting genetic alterations from histopathology of papillary thyroid carcinoma. Thyroid\u00ae 35:771\u2013780. https:\/\/doi.org\/10.1089\/thy.2024.0691","journal-title":"Thyroid\u00ae"},{"key":"2875_CR37","doi-asserted-by":"publisher","first-page":"23256","DOI":"10.1002\/gcc.23256","volume":"63","author":"JI Staubitz-Vernazza","year":"2024","unstructured":"Staubitz-Vernazza JI, M\u00fcller C, Heymans A et al (2024) Gene Expression Profiles of AHNAK2, DCSTAMP, FN1, and TERT Correlate With Mutational Status and Recurrence in Papillary Thyroid Carcinoma. Genes, Chromosom Cancer 63:23256. https:\/\/doi.org\/10.1002\/gcc.23256","journal-title":"Genes, Chromosom Cancer"},{"key":"2875_CR38","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/lary.30280","volume":"133","author":"A Abiri","year":"2023","unstructured":"Abiri A, Pang JC, Roman K et al (2023) Facility volume as a prognosticator of survival in locally advanced papillary thyroid cancer. Laryngoscope 133:443\u2013450. https:\/\/doi.org\/10.1002\/lary.30280","journal-title":"Laryngoscope"},{"key":"2875_CR39","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"Ringel MD, Sosa JA, Baloch Z et al (2025) 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid 35:841\u2013985. https:\/\/doi.org\/10.1177\/10507256251363120","journal-title":"Thyroid"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-026-02875-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-026-02875-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-026-02875-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:35:48Z","timestamp":1791297348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-026-02875-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":39,"alternative-id":["2875"],"URL":"https:\/\/doi.org\/10.1007\/s13304-026-02875-5","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}